

CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP

JUNE 2, 2021 VIRTUAL MEETING RECAP

The Central New Jersey Multiple Myeloma Support Group met virtually on June, 2, 2021 and had 28 members in attendance virtually.

Guest Speaker: Kimberly Gibbs, RN, BSN, OCN...Patient Liaison Takeda Pharmaceutical Company

Presentation: Cancer Survivorship: Optimizing Your Wellness

Announcements:

- **Steeplechase Cancer Center**
 - I recently spoke with our contact at Steeplechase Cancer Center, regarding in-person meetings. They advised me that there will be no in-person meetings for the remainder of 2021. They are hopeful to begin again in 2022. It is our hope to also provide a Zoom link for our in-person meetings, as long as the technology at Steeplechase supports this, so that those who cannot attend, can join us virtually.
- **Miracles for Myeloma 5K Virtual Run/Walk**
 - The 9th annual Miracles for Myeloma 5K Run/Walk will be virtual again this year, and will be held on September 18, 2021. Sheree and Ron Pask provided an update on the race and informed the group that the Miracles Website is up! Visit <http://give.myeloma.org/miracles2021>
 - You can join the Central Jersey Memorial Team (our group's team) when it is started, create your own team, or run/walk as an individual. You can also make a donation or sign up for the Remembrance Path.
 - Last year, Miracles 2020 was the **only fundraising event** to raise enough money to fund a research grant from the IMF.

- Visit the website for more information.

Reminder: There is no virtual meeting in July. See you on August 4th...Guest Speaker: Ann McNeil, RN, MSN, APN, Nurse Practitioner - Nurse Leadership Board, IMF

**Topic: Making Music with Your Healthcare Team
(great section on managing side effects)**

**CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP
JUNE 2, 2021 VIRTUAL MEETING RECAP
INFORMATIONAL MYELOMA LINKS**

International Myeloma Foundation

<https://www.myeloma.org/>

- **Virtual ASCO 2021 Includes Important New Data**
 - **Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results**
 - <https://www.myeloma.org/videos/idecabtagene-vicleucel-ide-cel-bb2121-bcma-directed-car-t-cell-therapy-relapsed-refractory>
- FDA Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment of Relapsed/Refractory Multiple Myeloma
- Week in Review by Dr. Brian Durie
 - First Results from Black Swan-Supported Iceland Study Published
- #AskDrDurie
 - What is the best diet for myeloma patients to build a strong immune system?

- Are steroids always used as part of myeloma treatment?

Multiple Myeloma Research Foundation (MMRF)

<https://themmrf.org/>

Myeloma Crowd

<https://www.myelomacrowd.org/>

- **ASCO 2021: Janssen Obtains FDA November 2021 Priority Review Date for Myeloma CAR T Cilta Cel Therapy**
 - <https://www.myelomacrowd.org/janssen-obtains-fda-november-2021-priority-review-date-for-myeloma-car-t-cilta-cel-therapy/>
- MCRT Webcast: BCMA and Other Targets
 - <https://www.myelomacrowd.org/mcrt-webcast-bcma-and-other-targets/>
- Salvage Therapy for Aggressive Types of Multiple Myeloma: Plasma Cell Leukemia and Extramedullary Myeloma
- ASCO 2021: Janssen Obtains FDA November 2021 Priority Review Date for Myeloma CAR T Cilta Cel Therapy
- Early Allo CAR T Results Targeting CS1 in Multiple Myeloma
- MC Community Event: Know Your Myeloma Therapy: BLENREP
- MRD and the Changing Myeloma Landscape
 - <https://www.myelomacrowd.org/mrd-and-the-changing-myeloma-landscape/>
- MC Community Event: How Multiple Myeloma Affects the Black Community with Dr. Craig Cole
- Clinical Trials: Venetoclax for Multiple Myeloma 11;14 Translocation Patients

- Clinical Trial: New Phase II Trial Opens for Pfizer's Multiple Myeloma Bispecific Antibody Elrantamab
- FDA Removes Clinical Trial Hold on Collectis Off-the-Shelf CAR T for Multiple Myeloma
- Mobilizing Stem Cells from Myeloma Patients prior to Stem Cell Transplant
 - <https://www.myelomacrowd.org/mobilizing-stem-cells-from-myeloma-patients-prior-to-stem-cell-transplant/>
- ASCO 2021: FDA grants Breakthrough Therapy Designation to Teclistamab, a Bispecific Antibody for Relapsed or Refractory Multiple Myeloma
 - <https://www.myelomacrowd.org/?e=our-next-show-early-antibodies-use-in-myeloma-care-for-newly-diagnosed-patients-with-peter-voorhees-md-levine-cancer-institute-may-18-10-am-eastern>
- **ASCO/EHA Meeting Review: Register Now for the Myeloma Crowd Round Table Webcast on June 26**
 - <https://www.myelomacrowd.org/asco-eha-meeting-review-register-now-for-the-myeloma-crowd-round-table-webcast-on-june-26/>
- Filing an Insurance Claim Appeal: The Internal Review Process- Part 1
 - <https://www.myelomacrowd.org/filing-an-insurance-claim-appeal-the-internal-review-process-part-1/>
- Filing an Insurance Claim Appeal: The External Review Process, Part 2
 - <https://www.myelomacrowd.org/you-need-to-file-an-insurance-appeal-external-review-process-part-2/>
- HealthTree University: MRD Testing (Part 1/3)
 - <https://www.myelomacrowd.org/watch-healthtree-university-mrd-testing-part-1-3-/>
- What is the progression of myeloma from precursor conditions to active myeloma?
 - <https://university.healthtree.org/app/lesson?id=Jh6zRHDOGo6MQhsgAGnf>

HealthTree University – YouTube

<https://www.youtube.com/channel/UC27i8v856WBGy-4ONPJS0MQ>

Myeloma Crowd Radio

<https://www.myelomacrowd.org/myeloma-crowd-radio-episodes/>

- Full Show: Treating Amyloidosis with Sascha Tuchman, MD, University of North Carolina

The Myeloma Beacon

<https://myelomabeacon.org/>

Myeloma Central

<https://www.myelomacentral.com/>

Cure

<https://www.curetoday.com/tumor/myeloma>

- How a Plasma Cell Disorder Called MGUS Can Progress to Multiple Myeloma

OnLive/OnLive Videos

<https://www.onlive.com/clinical/multiple-myeloma>

- Deep Responses Yielded by Cilta-Cel in Relapsed/Refractory Multiple Myeloma
- Ide-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma
- Allogeneic HCT Plus Reduced Intensity Conditioning With Bortezomib Triplet Is Safe in Multiple Myeloma
- Newly Approved Regimens for Relapsed/Refractory Multiple Myeloma

- Risk of Myeloma Relapse After Frontline Therapy
- An Expanding Armamentarium Calls for Tailored Therapy in Relapsed/Refractory Myeloma
 - <https://www.onclive.com/view/an-expanding-armamentarium-calls-for-tailored-therapy-in-relapsed-refractory-myeloma>
- Plus, much more!

Myeloma Research News

<https://myelomaresearchnews.com/>

Myeloma Hub

<https://multiplemyelomahub.com/>

- Positive topline results of the phase III OCEAN study of melflufen for RRMM
- Ixazomib, lenalidomide, and dexamethasone as first-line therapy: Tourmaline-MM2 trial update
- “How I treat patients with MRD after transplantation”
- Multiple Myeloma Hub Satellite Symposium highlights: Should cure be the goal for MM?
- Treating elderly and frail patients with MM: Cure versus disease control
 - <https://multiplemyelomahub.com/medical-information/treating-elderly-and-frail-patients-with-mm-cure-versus-disease-control>
- When is the optimal time to start talking with your patient about CAR T cells?
 - <https://multiplemyelomahub.com/medical-information/when-is-the-optimal-time-to-start-talking-with-your-patient-about-car-t-cells>
- Salvage auto-HCT outcomes with remobilized stem cells in multiple myeloma
 - <https://multiplemyelomahub.com/medical-information/salvage-auto-hct-outcomes-with-remobilized-stem-cells-in-multiple-myeloma>

Cancer.com

<https://www.cancer.com/>

Patient Power

<https://patientpower.info/multiple-myeloma/>

- **Myeloma Connections: Dinner with the Docs**
 - <https://patientpower.info/events/event/myeloma-connections-dinner-with-the-docs-june-14/2021-06-14/1800>
 - **Monday, June 14th, at 6 pm EST**
 - **6:00 PM – 8:00 PM Eastern Time**
 - **This exciting and informative discussion is your chance to connect with local multiple myeloma experts.**
- Biochemical Relapse in Multiple Myeloma Patients
- What Role Does Dexamethasone Play in Myeloma Treatment?

American Society of Hematology (ASH)

<https://www.hematology.org/>

ASH Clinical News

<https://www.ashclinicalnews.org>

- Pain Pointers - Early intervention and careful management are critical in the treatment of peripheral neuropathy

Blood Journal

<https://ashpublications.org/blood>

- Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma
- Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
 - <https://www.nature.com/articles/s41408-021-00480-w>

The Lancet

<https://www.thelancet.com/action/doSearch?text1=myeloma&field1=AllField>

- Current Issue
 - <https://www.thelancet.com/journals/lanhae/issue/current>
 - Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy
 - Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-center, phase 2 trial
 - CAR T-cell therapy for multiple myeloma: state of the art and prospects

Healio

<https://www.healio.com/search?q=myeloma&sort=relevancy>

- CAR-T provides superior efficacy for multiple myeloma at higher cost, report states

Leukemia/Lymphoma Society (LLS)

<https://www.lls.org/>

- Nearly half of cancer patients in Medicare Part D don't take life-saving medication when their prescription costs more than \$2,000 to fill
 - <https://ils.org/advocate/nearly-half-cancer-patients-medicare-part-d-dont-take-life-saving-medication-when-their>

MYeloma Channel

<https://myelomachannel.com/>

Jama Oncology

<https://jamanetwork.com/journals/jama/article-abstract/2779566?resultClick=1>

- Cell-Based Gene Therapy Is New Option for Multiple Myeloma

Patient Empowerment Network

<https://powerfulpatients.org/help-by-cancer-diagnosis/multiple-myeloma/>

Managing Myeloma

<https://www.managingmyeloma.com/>

The Cancer Journal

<https://journals.lww.com/journalppo/pages/currenttoc.aspx>

- “If You Don't Stop to Look Around Once in a While... You Could Miss It”
- From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma?
- Smoldering Myeloma Treatment: Who, What, and When
- Induction Therapy Strategies in the Transplant-Ineligible Population
- Strategies to Overcome High-Risk Multiple Myeloma

- Plus, more!

Abecma CAR t-cell Therapy

<https://www.abecma.com/>

DocWireNews

<https://www.docwirenews.com/condition-center/multiple-myeloma-knowledge-hub/multiple-myeloma-picks/bcma-loss-during-multiple-myeloma-therapy-with-dr-nikhil-munshi/>

- BCMA Loss During Multiple Myeloma Therapy, with Dr. Nikhil Munshi

Pharmaphorum

<https://pharmaphorum.com/news/straight-after-its-first-cancer-bispecific-ok-jj-highlights-two-more-at-asco/>

- Straight after its first cancer bispecific OK, J&J highlights two more at ASCO

Biospace

<https://www.biospace.com/article/legend-biotech-s-ceo-ying-huang-on-cilta-cel-s-high-pfs-in-myeloma-patients/>

- Legend Biotech's CEO Ying Huang on Cilta-cel's High PFS in Myeloma Patients

Biopharm International

- Janssen Receives FDA Breakthrough Therapy Designation for Multiple Myeloma mAb
 - <https://www.biopharminternational.com/view/janssen-receives-fda-breakthrough-therapy-designation-for-multiple-myeloma-mab>

OncologyTube.Com

- Brian Durie, MD
 - With 80,000 Participants, the Largest Study of Its Kind Is the First to Evaluate the Benefits of Screening – istopMM
 - <https://www.oncologytube.com/video/39980/brian-durie-md-brianduriemd-imfmyeloma-multiplemyeloma-cancer-research-with-80-000-participants-the-largest-study-of-its-kind-is-the-first-to-evaluate-the-benefits-of-screening>

Business Wire

- U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma
 - <https://www.businesswire.com/news/home/20210526006114/en/U.S.-Food-and-Drug-Administration-Grants-BCMA-CAR-T-Cilta-cel-Priority-Review-for-the-Treatment-for-RelapsedRefractory-Multiple-Myeloma>

TedTalks

https://www.ted.com/talks/carl_june_a_living_drug_that_could_change_the_way_we_treat_cancer

- A 2018 TedTalk on CART-cell therapy that is worth watching, now that CART-cell therapy is here for Myeloma

CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP

JUNE 2, 2021 VIRTUAL MEETING RECAP

COVID-19/MYELOMA LINKS

International Myeloma Foundation

- Staying Safe for the Holiday

- <https://www.myeloma.org/blog/staying-safe-holiday>
- #ASKDRDURIE COVID-19 FAQs
 - <https://www.myeloma.org/covid19-myeloma-patients>
 - Can COVID-19 vaccinations trigger active myeloma?
 - Should myeloma patients check their COVID-19 antibody levels post vaccination?
 - When can myeloma patients restart therapy after recovering from COVID-19?
 - How common are COVID-19 infections in myeloma patients?
 - Which COVID-19 vaccine should myeloma patients get?

Myeloma Crowd

- Pfizer COVID Vaccine Impact on Multiple Myeloma Italian Patients
 - <https://www.myelomacrowd.org/update-on-covid-vaccine-impact-on-multiple-myeloma-patients/>

Cure

- Significant Number of Oncology Patients May be Experiencing Loneliness and Symptom Burden Due to COVID-19 Pandemic
 - <https://www.curetoday.com/view/significant-number-of-oncology-patients-may-be-experiencing-loneliness-and-symptom-burden-due-to-covid-19-pandemic>
- Pfizer-BioNTech Booster Vaccine Significantly Improves Immune Responses in Patients With Cancer
 - <https://www.curetoday.com/view/pfizer-biontech-booster-vaccine-significantly-improves-immune-responses-in-patients-with-cancer>

CureTalks

- The Double Whammy of Cancer and COVID-19 on Mental Health
 - <https://www.curetoday.com/view/the-double-whammy-of-cancer-and-covid-19-on-mental-health>
- Drug Repurposing for COVID-19 with CORONA Registry (COVID-19 Registry of Off-label & New Agents)
 - **Covid 19 Convalescent Plasma Study**
 - <https://www.curetalks.com/?s=covid+19>

NY Post

- Coronavirus vaccines may not work in some people. It's because of their underlying conditions
 - <https://www.washingtonpost.com/health/2021/05/18/immunocompromised-coronavirus-vaccines-response/>

Nature

- Scientists zero in on long-sought marker of COVID-vaccine efficacy
 - <https://www.nature.com/articles/d41586-021-01372-6>